Chemoradiation is the standard therapy for the majority of inoperable, locally advanced
cancers. Although there is a need to improve chemoradiation efficacy, normal-tissue toxicity …

This paper explores historical and current roles of pharmaceutical industry sponsorship of
clinical trials testing radiation therapy combinations with molecularly targeted agents and …

In the era of precision medicine, radiation medicine is currently focused on the precise
delivery of highly conformal radiation treatments. However, the tremendous developments in …

Newer technical improvements in radiation oncology have been rapidly implemented in
recent decades, allowing an improved therapeutic ratio. The development of strategies …

DNA double-strand breaks are the critical lesions responsible for the majority of ionizing
radiation–induced cell killing. Thus, the ability of tumor cells to elicit a DNA damage …

While the advent of combined chemoradiation has improved outcomes for innumerable
patients with locally advanced cancers, further improvements are urgently needed …

The development of molecular targeted therapeutics in oncology builds on many years of
scientific investigation into the cellular mechanics of malignant transformation and …

Radiotherapy is a standard cytotoxic therapy against solid cancers. It uses ionizing radiation
to kill tumor cells through damage to DNA, either directly or indirectly. Radioresistance is …

The ideal radiation sensitizer would reach the tumor in adequate concentrations and act
selectively in the tumor compared with normal tissue. It would have predictable …

Radiotherapy continues to remain a major treatment modality for solid tumors. However,
advances in fundamental radiobiology suggest that improvements in tumor control can be …